Eli Lilly & Co. (LLY) Announces New Data from Verzenio monarchE Study to Be Featured in ESMO Virtual Plenary
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 0.7%
EPS Growth %: +51.9%
Join SI Premium – FREE
New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine therapy, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) high risk early breast cancer will be presented at the October 14 European Society for Medical Oncology (ESMO) Virtual Plenary.
Details on this presentation are shared below.
Presentation Date and Time: | Thursday, October 14 at 19:30 CEST |
Title: | Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE |
Authors: | J. O'Shaughnessy et al. |
Publication Number: | VP8_2021 |
The presentation will utilize an April 2021 data cutoff date, allowing for more follow-up relative to the analysis last presented at the San Antonio Breast Cancer Symposium in December 2020.
The abstract is embargoed until the start of the Virtual Plenary session. For more information, please visit: https://www.esmo.org/meetings/october-virtual-plenary-2021.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Day One Biopharmaceuticals' (DAWN) OJEMDA Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
- Day One Biopharmaceuticals' (DAWN) OJEMDA receives FDA approval.
- Independent Bank (IBCP) Appoints Stephen L. Gulis, Jr. as Board Chair
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
